Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis

International Journal of Experimental Pathology

Volumn 89, Issue 4, 2008, Pages 241-250

  Leung, Tung Ming ^a,b   Tipoe, George L ^b   Liong, Emily C ^b   Lau, Thomas Y H ^c   Fung, Man Lung ^b   Nanji, Amin A ^a,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d MacKenzie Building ^*  (Canada)

Author keywords

Carbon tetrachloride; Chronic liver injury; L arginine; Nitric oxide synthase

Indexed keywords

5 METHYLISOTHIOUREA HEMISULFATE; 8 ISOPROSTANE; ALANINE AMINOTRANSFERASE; ARGININE; CARBON TETRACHLORIDE; COLLAGEN; DEXTRO ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE INHIBITOR; THIOUREA DERIVATIVE; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROGENESIS; GEL MOBILITY SHIFT ASSAY; LIVER BLOOD FLOW; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; ARGININE; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CHRONIC DISEASE; DISEASE PROGRESSION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ISOTHIURONIUM; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED ICR; MODELS, ANIMAL; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROCOLLAGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 47649120300     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00590.x     Document Type: Article

References (44)

1. Ballet F., Chretien Y., Rey C., Poupon R. (1988) Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. 244, 283 289.
2. Bataller R. Brenner D.A. (2005) Liver fibrosis. J. Clin. Invest. 115, 209 218.
3. Bataller R., Nicolas J.M., Ginees P. et al. (1998) Contraction of human hepatic stellate cells activated in culture: a role for voltage-operated calcium channels. J. Hepatol. 29, 398 408.
4. Bataller R., Gines P., Nicolas J.M. et al. (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118, 1149 1156.
5. Berka V., Wu G., Yeh H.C., Palmer G., Tsai A.L. (2004) Three different oxygen-induced radical species in endothelial nitric-oxide synthase oxygenase domain under regulation by l-arginine and tetrahydrobiopterin. J. Biol. Chem. 279, 32243 32251.
6. Bhathal P.S. Grossman H.J. (1985) Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J. Hepatol. 1, 325 337.
7. Bissell D.M. (1998) Hepatic fibrosis as wound repair: a progress report. J. Gastroenterol. 33, 295 302.
8. Blaise G.A., Gauvin D., Gangal M., Authier S. (2005) Nitric oxide, cell signaling and cell death. Toxicology 208, 177 192.
9. Bruckdorfer R. (2005) The basics about nitric oxide. Mol. Aspects Med. 26, 3 31.
10. Cahill P.A., Redmond E.M., Sitzmann J.V. (2001) Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol. Ther. 89, 273 293.
11. Canty E.G. Kadler K.E. (2005) Procollagen trafficking, processing and fibrillogenesis. J. Cell Sci. 118, 1341 1353.
12. Coskun U., Ozenirler S., Sancak B., Bukan N. (2001) Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin. Chim. Acta 306, 127 132.
13. Fiorucci S., Antonelli E., Morelli O. et al. (2001) NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc. Natl. Acad. Sci. U.S.A. 98, 8897 8902.
14. Garcia-Pagan J.C., Bosch J., Rodes J. (1995) The role of vasoactive mediators in portal hypertension. Semin. Gastrointest. 6, 140 147.
15. Garcia-Pagan J.C., Escorsell A., Moitinho E., Bosch J. (1999) Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin. Liver Dis. 19, 427 438.
16. Giannelli G., Quaranta V., Antonaci S. (2003) Tissue remodelling in liver diseases. Histol. Histopathol. 18, 1267 1274.
17. Gines P., Cardenas A., Arroyo V., Rodes J. (2004) Management of cirrhosis and ascites. N. Engl. J. Med. 350, 1646 1654.
18. Gupta T.K., Toruner M., Chung M.K., Groszmann R.J. (1998) Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28, 926 931.
19. Hoffmann A., Gloe T., Pohl U. (2001) Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J. Cell Physiol. 188, 33 44.
20. Jung S.A., Chung Y.H., Park N.H. et al. (2000) Experimental model of hepatic fibrosis following repeated periportal necrosis induced by allylalcohol. Scand. J. Gastroenterol. 35, 969 975.
21. Kakumitsu S., Shijo H., Yokoyama M. et al. (1998) Effects of l-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis. Hepatology 27, 377 382.
22. Kohli R., Meininger C.J., Haynes T.E., Yan W., Self J.T., Wu G. (2004) Dietary l-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J. Nutr. 134, 600 608.
23. Laroux F.S., Pavlick K.P., Hines I.N. et al. (2001) Role of nitric oxide in inflammation. Acta Physiol. Scand. 173, 113 118.
24. Lass A., Suessenbacher A., Wolkart G., Mayer B., Brunner F. (2002) Functional and analytical evidence for scavenging of oxygen radicals by l-arginine. Mol. Pharmacol. 61, 1081 1088.
25. Leifeld L., Fielenbach M., Dumoulin F.L., Speidel N., Sauerbruch T., Spengler U. (2002) Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J. Hepatol. 37, 613 619.
26. Li X., Meng Y., Wu P., Zhang Z., Yang X. (2007) Angiotensin II and Aldosterone stimulating NF-κB and AP-1 activation in hepatic fibrosis of rat. Regul. Pept. 138, 15 25.
27. Loureiro-Silva M.R., Cadelina G.W., Groszmann R.J. (2003) Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G567 G574.
28. Marek A., Brodzicki J., Liberek A., Korzon M. (2002) TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med. Sci. Monit. 8, RA145 RA151.
29. Marletta M.A., Hurshman A.R., Rusche K.M. (1998) Catalysis by nitric oxide synthase. Curr. Opin. Chem. Biol. 2, 656 663.
30. Marshall R.P., McAnulty R.J., Laurent G.J. (2000) Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am. J. Respir. Crit. Care Med. 161, 1999 2004.
31. Meininger C.J., Marinos R.S., Hatakeyama K. et al. (2000) Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem. J. 349, 353 356.
32. Milani S., Schuppan D., Herbst H., Surrenti C. (1992) Expression of transforming growth factor- in normal and fibrotic human liver. In : Molecular and Cell Biology of Liver Fibrogenesis: Proceedings of the International Falk Symposium, pp. 254 261 (ed A.M.R.G. Gressner Germany : Kluwer Academic Publishers.
33. Milani S., Herbst H., Schuppan D., Grappone C., Heinrichs O.E. (1995) Cellular sources of extracellular matrix proteins in normal and fibrotic liver. Studies of gene expression by in situ hybridization. J. Hepatol. 22 (2 Suppl. 71 76.
34. Mittal M.K., Gupta T.K., Lee F.Y., Sieber C.C., Groszmann R.J. (1994) Nitric oxide modulates hepatic vascular tone in normal rat liver. Am. J. Physiol 267, G416 G422.
35. Moncada S. (1999) Nitric oxide: discovery and impact on clinical medicine. J. R. Soc. Med. 92, 164 169.
36. Moussa Y.I., Plevris J.N., Hayes P.C. (2000) Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 12, 159 163.
37. Palmer R.M., Ferrige A.G., Moncada S. (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524 526.
38. Petermann H., Vogl S., Schulze E., Dargel R. (1999) Chronic liver injury alters basal and stimulated nitric oxide production and 3H-thymidine incorporation in cultured sinusoidal endothelial cells from rats. J. Hepatol. 31, 284 292.
39. Schmidt K., Werner E.R., Mayer B., Wachter H., Kukovetz W.R. (1992) Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem. J. 281, 297 300.
40. Shah V., Toruner M., Haddad F. et al. (1999) Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117, 1222 1228.
41. Tipoe G.L., Leung T.M., Liong E. et al. (2006) Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury. Histol. Histopathol. 21, 1157 1165.
42. Vallance P. Moncada S. (1991) Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 337, 776 778.
43. Wei C.L., Khoo H.E., Lee K.H., Hon W.M. (2002) Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats. Nitric Oxide 7, 91 102.
44. Yoshiji H., Kuriyama S., Noguchi R. et al. (2006) Angiotensin II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol. Res. 36, 124 129.